Sartorius Appoints Internatio?nally Experience?d Laboratory Manager to Join its Top Management Team
Effective 1 April 2014, Michael Melingo will head marketing, sales and services of the Lab Products & Services Division at Sartorius. He will therefore succeed Dominique Baly, who will retire from the company as planned after reaching retirement age. Michael Melingo will report to CEO and Executive Board Chairman Dr Joachim Kreuzburg and be a member of the Group Executive Committee, the highest operational management level of the Sartorius Group.
Michael Melingo, who brings more than 30 years of experience in the industry as a sales and marketing executive, will be joining Sartorius from Metrohm, the Swiss manufacturer of analytical instruments, where he was CEO of its US subsidiary. Before that, he had worked for Baxter, Bio-Rad, Millipore and Waters in Europe and Asia. Michael Melingo is of Austrian nationality and a bioengineer who specializes in biochemistry and food technology.
“With Michael, we have found an exceptionally experienced manager to join our team, who has successfully managed international laboratory businesses. In his new role at Sartorius, he will focus on further developing the global sales, marketing and service organization of our laboratory division business and strengthen its strategic positioning,” said Sartorius CEO and Executive Board Chairman Joachim Kreuzburg.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...